{
    "address": "Scheelevagen 22, P.O. Box 785",
    "city": "Lund",
    "country": "SE",
    "currency": "SEK",
    "cusip": "W4307Q109",
    "description": "Hansa Biopharma AB focuses on novel immunomodulatory enzymes, which treats rare immunoglobulin G-mediated autoimmune conditions, transplant rejection and cancer. The company is headquartered in Lund, Skane and currently employs 101 full-time employees. The company went IPO on 2007-10-17. The Company\u2019s operations consist of research and development for drug discovery. The firm conducts several projects, among which primary are IdeS (Immunoglobulin G-degrading enzyme of Streptococcus pyogenes) and HBP-assay (Heparin Binding Protein-assay). IdeS\u2019s goal is to enable transplantation that prevents antibody-mediated rejection. HBP-assay is a diagnostic method that aims to predict severe sepsis in patients with infectious disease symptoms. The Company\u2019s patent portfolio consists of several patent families that geographically cover numerous jurisdictions, including the United States, Europe and Japan.",
    "employeeTotal": "101.0",
    "exchange": "NASDAQ OMX NORDIC",
    "finnhubIndustry": "Biotechnology",
    "ggroup": "Pharmaceuticals, Biotechnology & Life Sciences",
    "gind": "Biotechnology",
    "gsector": "Health Care",
    "gsubind": "Biotechnology",
    "ipo": "2007-10-17",
    "isin": "SE0002148817",
    "logo": "https://finnhub.io/api/logo?symbol=HNSA.ST",
    "marketCapitalization": 6495.348,
    "naics": "Scientific Research and Development Services",
    "naicsNationalIndustry": "Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)",
    "naicsSector": "Professional, Scientific, and Technical Services",
    "naicsSubsector": "Professional, Scientific, and Technical Services",
    "name": "Hansa Biopharma AB",
    "phone": "4646165670.0",
    "sedol": "B2827W2",
    "shareOutstanding": 44.473452,
    "state": "SKANE",
    "ticker": "HNSA.ST",
    "weburl": "https://hansamedical.com/"
}